Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging for its superior sensitivity to X-ray.

Readouts this year will help determine whether either method can demonstrate a slowing of already slow disease progression in osteoarthritis (OA) patients...